ESIC DG Ayurvedic Rate Contract Ay-10 Tender 2026 - eTender
The Directorate General ESIC has issued the eTender Enquiry Form for the DG ESIC Ayurvedic Rate Contract No. Ay-10 covering Classical Ayurvedic Drugs and Formulations, with a Corrigendum and Clarification document dated 20 February 2026 incorporating revised WHO-GMP, Turnover, Audited Financial Statement, Authorized Signatory, Drug Price Control, Annexure G, Annexure D-1 / D-2, Packing and Drug Schedule clauses. The tender carries File reference U-16013/141/2022-AYUSH and is signed under the authority of the Deputy Medical Commissioner (Ayush) for the Director General.
Quick Glance
Rate Contract Ay-10 · File Ref U-16013/141/2022-AYUSH · Corrigendum 20 February 2026 · WHO-GMP Now mandatory if 3+ qualified bids · Turnover Multiple 4x revised
Overview
Organisation - Employees' State Insurance Corporation (ESIC), Ministry of Labour and Employment
Issuing Office - Directorate General ESIC, AYUSH Section, New Delhi
Rate Contract Number - DG ESIC Ayurvedic Rate Contract No. Ay-10
File Reference - U-16013/141/2022-AYUSH
Subject - eTender Enquiry form for DG ESIC Ayurvedic Rate Contract for Classical Ayurvedic Drugs and Formulations
Corrigendum Date - 20 February 2026
Clarification Date - 20 February 2026 (post-pre-bid)
Bid Mode - e-Tender on the CPP Portal
EMD - Drug-wise EMD amount specified in Annexure-1 (MSE and Startup exempt under clause 2.9)
Console Sl. No. - 15645/2026
Signing Authority for Corrigendum and Clarification - Deputy Medical Commissioner (Ayush) for Director General
Important Links
Download eTender Enquiry Form (DG ESIC Ayurvedic RC Ay-10): https://esic.gov.in/attachments/tenderfile/eTender_Enquiry_form_for_DG_ESIC_Ayurvedic_Rate_Contract_No_Ay_10_English_1771589718.pdf
Download Annexure D-1 D-2 (Revised): https://esic.gov.in/attachments/tenderfile/Annexure_D1_D2_1771589718.pdf
Download Annexure G (Revised, on Rs 100 non-judicial stamp paper, notarized): https://esic.gov.in/attachments/tenderfile/Annexure_G_1771589718.pdf
Download Check List: https://esic.gov.in/attachments/tenderfile/Check_list_1771589718.pdf
Download Drug Schedule (with EMD, PS and Turnover): https://esic.gov.in/attachments/tenderfile/Drug_Schedule_with_EMD_PS_and_Turnover_1771589718.pdf
Download Pre-Bid Clarification: https://esic.gov.in/attachments/tenderfile/Clarification_w_r_t_to_queries_raised_sent_by_firms_with_regards_to_pre_bid_meeting_of_Tender_Enquiry_form_for_DG_ESIC_Ayurvedic_Rate_Contract_No_Ay_10_English_1771589718.pdf
CPP Portal (Central Public Procurement Portal): https://eprocure.gov.in/eprocure/app
ESIC Tenders Page (Official): https://esic.gov.in/tenders/index
Tender Details
The DG ESIC Ayurvedic Rate Contract Ay-10 is a centralised eTender enquiry by the Directorate General ESIC to set up a Rate Contract for the supply of Classical Ayurvedic Drugs and Formulations across ESIC facilities. The Drug Schedule (Annexure-1 / Drug Schedule with EMD, PS and Turnover) lists Classical Ayurvedic drugs across groups such as Shastrokta Yogas / Special, Sandhana Kalpana, Churna Kalpana etc., with packing sizes specified as 2 gm / 16 tab or 2 gm / 20 tab for the tablet preparations.
The Corrigendum dated 20 February 2026 has approved the following changes to the original tender enquiry. These changes are binding on every participating firm and supplement the original tender enquiry form. The pre-bid Clarification (also dated 20 February 2026) addresses firm-side queries raised during the pre-bid meeting and is to be read along with the Corrigendum.
Key Revised Clauses (Corrigendum + Clarification)
WHO-GMP (Clause 5.5) - Participating firms must hold a valid WHO-GMP or GMP certificate for the manufacturing site of the quoted drugs as on the Bid Submission End date. In cases where 3 or more technically qualified WHO-GMP bids exist for a particular drug, only WHO-GMP firms will be considered. If fewer than 3 WHO-GMP firms technically qualify, firms with GMP certificates will also be considered for that drug.
Turnover (Annexure 2) - Revised item-wise turnover requirement enclosed in the corrigendum. Aggregate turnover for all quoted drugs by a bidder is considered, not the bidder's total turnover. The annual turnover multiple is reduced from 5x (500 percent) to 4x (400 percent) of the estimated ESIC expenditure on Ayurvedic drugs. Relaxation to MSEs and Startup firms is already considered in Annexure-2.
Audited Financial Statement (Clause 7.e and Checklist No. 9) - Submit audited financial statement (Balance Sheet and Profit and Loss Account Statement) in respect of annual turnover for the firm as a whole for the three years (i.e. 2022-23, 2023-24 and 2024-25). The earlier requirement to highlight Ayurvedic-drugs turnover separately has been removed.
Authorized Signatory (Clause 25.1 C) - For companies, enclose the resolution of the Board of Directors OR Power of Attorney (POA). Both are acceptable.
Drug Price Control (Clause 5.12) - The Participating Pharmaceutical firm or stores should comply with the provisions of the Drugs and Cosmetics Act 1940 and the Rules 1945 made thereunder as amended upto date. The phrase "Drug Price Control Order" is removed since it is not applicable to Ayurvedic drugs.
Annexure G - Revised Annexure G enclosed; to be submitted on Rs 100 non-judicial stamp paper and notarized.
Annexure D-1 and D-2 - Revised Annexure D-1 and D-2 enclosed; "Number of Batches" considered in place of individual "Batch Numbers" in Sl. No. 6, to reduce document bulkiness.
Packing (Clause 10.14 / 10.15) - The weight of each pill / tablet of drugs packing 2 gm should be 100 mg or 125 mg (2 gm / 20 Tabs or 2 gm / 16 Tabs). The weight of each pill / tablet of Karpoor Rasa should be 100 mg or 125 mg (2 gm / 20 Tabs or 2 gm / 16 Tabs).
Drug Schedule - Makardhwaja Vati (B.R) is substituted at Sl. No. 12 of the Classical Drug Schedule in place of the earlier Makardhwaja Vati (AFI). The Drug Schedule along with Annexure 1 and Annexure 2 also includes the same modification (enclosed).
EMD (Clause 2) - Drug-wise EMD amount is specified in Annexure-1. EMD is required to be submitted by bidders for all drugs quoted. However, MSEs and Start-ups are exempt from paying the EMD under clause 2.9.
Eligibility and Compliance
The corrigendum and clarification together enforce the following compliance posture on the participating firm. The firm must hold a valid WHO-GMP or GMP certificate for the manufacturing site of every quoted drug as on the Bid Submission End date, with the WHO-GMP-only rule applied when the technically qualified WHO-GMP bid count is 3 or more for any specific drug. The firm must submit audited Balance Sheet and Profit and Loss Account Statement for the firm as a whole for FY 2022-23, 2023-24 and 2024-25. The firm must satisfy the revised turnover requirement at 4 times (400 percent) the estimated ESIC expenditure on the quoted drugs, in aggregate across all drugs quoted. MSE-registered manufacturers and DPIIT-registered startups receive turnover relaxation under Annexure-2 and EMD exemption under Clause 2.9.
The firm must also submit the revised Annexure G on Rs 100 non-judicial stamp paper, duly notarized; the revised Annexure D-1 and D-2 capturing "Number of Batches" instead of individual batch numbers; and the standard Drug Schedule compliance, with packing weight of 100 mg / 125 mg for the 2 gm tablet preparations.
Important Instructions
The revised tender clauses, Annexures D-1 / D-2 / G, Drug Schedule and packing rules supersede the originally issued enquiry form to that extent. Rest of the terms and conditions of the Tender Enquiry and Drug Schedule remain the same.
The WHO-GMP vs GMP rule is conditional - WHO-GMP only if 3+ WHO-GMP bids qualify; otherwise GMP firms are also considered for that specific drug.
Turnover requirement is in aggregate for all quoted drugs, capped at 4x (not 5x) of the estimated ESIC expenditure. Per CVC reference, GFR or Manual for Procurement of Goods (2024) does not restrict to any multiple; GeM also allows 4x.
Annexure G must be on Rs 100 non-judicial stamp paper and notarized; an unstamped or un-notarized Annexure G is liable to be rejected.
For companies, the bid signing authority can be evidenced either via Board Resolution or via Power of Attorney - both are now valid alternatives.
Drug Price Control Order phrase is removed from Clause 5.12 since it does not apply to Ayurvedic drugs - bidders must instead comply with Drugs and Cosmetics Act 1940 and Rules 1945 (as amended).
EMD is drug-wise per Annexure-1; MSEs and Startups are exempt under Clause 2.9 subject to valid Udyam Registration / DPIIT recognition.
The Corrigendum and Clarification are both issued with the approval of the Competent Authority by the Deputy Medical Commissioner (Ayush) for the Director General.
Final Words
The ESIC DG Ayurvedic Rate Contract Ay-10 Tender 2026 is a centralised eTender to set up a multi-drug Rate Contract for Classical Ayurvedic preparations supplied across ESIC facilities. The 20 February 2026 Corrigendum and Clarification together relax WHO-GMP enforcement to a conditional 3-bid rule, reduce the turnover multiple to 4x, simplify the financial-statement requirement to the firm-wide audited accounts, allow either Board Resolution or POA for company signatory and standardise the packing weight to 100 mg / 125 mg for 2 gm tablets. Ayurvedic drug manufacturers with WHO-GMP / GMP compliance should follow these revised clauses while submitting on the CPP Portal. For more DG ESIC Ayurvedic procurement updates, keep visiting SarkariWorld.org.